| Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway D Kumar, S Shankar, RK Srivastava Cancer letters 343 (2), 179-189, 2014 | 220 | 2014 |
| Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells BN Singh, D Kumar, S Shankar, RK Srivastava Biochemical pharmacology 84 (9), 1154-1163, 2012 | 218 | 2012 |
| Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy S Raj, S Khurana, R Choudhari, KK Kesari, MA Kamal, N Garg, ... Seminars in cancer biology 69, 166-177, 2021 | 144 | 2021 |
| Biomolecular characterization of exosomes released from cancer stem cells: possible implications for biomarker and treatment of cancer D Kumar, D Gupta, S Shankar, RK Srivastava Oncotarget 6 (5), 3280, 2015 | 141 | 2015 |
| Epigenetic modifications by dietary phytochemicals: implications for personalized nutrition S Shankar, D Kumar, RK Srivastava Pharmacology & therapeutics 138 (1), 1-17, 2013 | 136 | 2013 |
| Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: molecular mechanisms D Kumar, S Shankar, RK Srivastava Molecular cancer 12 (1), 1-15, 2013 | 135 | 2013 |
| Oxidative stress in cancer cell metabolism S Arfin, NK Jha, SK Jha, KK Kesari, J Ruokolainen, S Roychoudhury, ... Antioxidants 10 (5), 642, 2021 | 132 | 2021 |
| NVP-LDE-225 (Erismodegib) inhibits epithelial–mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128 R Nanta, D Kumar, D Meeker, M Rodova, PJV Veldhuizen, ... Oncogenesis 2 (42), 2013 | 112 | 2013 |
| Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations DK Jha NK, Ojha S, Jha SK, Dureja H, Singh SK, Shukla SD, Chellappan DK ... Journal of Molecular Neuroscience, www.doi/10.1007/s12031-020-01767-6, 2021 | 101* | 2021 |
| Cancer-associated fibroblasts drive glycolysis in a targetable signaling loop implicated in head and neck squamous cell carcinoma progression D Kumar, J New, V Vishwakarma, R Joshi, J Enders, F Lin, S Dasari, ... Cancer research 78 (14), 3769-3782, 2018 | 95 | 2018 |
| Discovery of New Hydroxyethylamine Analogs against 3CLpro Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure … S Kumar, PP Sharma, U Shankar, D Kumar, SK Joshi, L Pena, ... Journal of chemical information and modeling 60 (12), 5754-5770, 2020 | 93 | 2020 |
| In silico identification of potent FDA approved drugs against Coronavirus COVID-19 main protease: A drug repurposing approach D Kumar, V Chandel, S Raj, B Rathi Chemical Biology Letters 7 (3), 166-175, 2020 | 89 | 2020 |
| Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway S Kumar, H S Patil, P Sharma, D Kumar, S Dasari, V G Puranik, ... Current Molecular Medicine 12 (8), 952-966, 2012 | 77 | 2012 |
| Arsenic exposure in Indo Gangetic plains of Bihar causing increased cancer risk A Kumar, M Ali, R Kumar, M Kumar, P Sagar, RK Pandey, V Akhouri, ... Scientific Reports 11 (1), 2376, 2021 | 59 | 2021 |
| The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity N Plotegher, D Kumar, I Tessari, M Brucale, F Munari, L Tosatto, ... Human molecular genetics 23 (21), 5615-5629, 2014 | 59 | 2014 |
| In silico identification of potent COVID-19 main protease inhibitors from FDA approved antiviral compounds and active phytochemicals through molecular docking: A drug … V Chandel, S Raj, B Rathi, D Kumar MDPI AG, 2020 | 54 | 2020 |
| Covalent α-synuclein dimers: chemico-physical and aggregation properties M Pivato, G De Franceschi, L Tosatto, E Frare, D Kumar, D Aioanei, ... PloS one 7 (12), e50027, 2012 | 46 | 2012 |
| Mitigation of tumor-associated fibroblast-facilitated head and neck cancer progression with anti–hepatocyte growth factor antibody ficlatuzumab D Kumar, C Kandl, CDA Hamilton, Y Shnayder, TT Tsue, K Kakarala, ... JAMA Otolaryngology–Head & Neck Surgery 141 (12), 1133-1139, 2015 | 45 | 2015 |
| Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2 V Chandel, PP Sharma, S Raj, R Choudhari, B Rathi, D Kumar Journal of Biomolecular Structure and Dynamics 40 (1), 249-262, 2022 | 41 | 2022 |
| The degree of intratumor mutational heterogeneity varies by primary tumor sub-site TSM Ledgerwood LG, Kumar D, Eterovic AK, Wick J, Chen K, Zhao H, Tazi L ... Oncotarget, 2016 | 40 | 2016 |
Luigi BubaccoDipartimento di Biologia , Universitą degli Studi di Padova, ItalyVerified email at unipd.it
